The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.

Inclusion Criteria:

• Age 70 years
• Histological diagnosis of Renal Cell Carcinoma (any histology, with the exclusion of urothelial carcinomas)
• Locally advanced disease or metastatic disease (any site, measurable or non- measurable lesions), progressing after at least one line of VEGFR-targeted therapy (as per official registration of the drug at AIFA, in case of extension to first-line treatment, TKI-naïve patients will also be eligible), with or without previous exposure to check-point inhibitors.
• Life expectancy of at least 3 months
• Adequate hepatic, renal and bone marrow function as judged by the treating oncologist.
• Written informed consent

Exclusion Criteria:

• Inability to swallow cabozantinib tablets
• Serious comorbidities or cognitive impairment, which may interfere with cabozantinib administration and/or patient's follow up, as judged by the treating physician
• Absence of a reliable caregiver, as judged by the treating physician

Patients will be enrolled from Italian oncology Centers